No, Pres­i­dent Trump, bio­phar­ma does not want you to dereg­u­late drug de­vel­op­ment

Nobody wants rad­i­cal changes at the FDA, ex­cept per­haps Pres­i­dent Trump and a few close as­so­ciates.

We’ve been track­ing the in­dus­try’s clear re­luc­tance to dis­card the FDA gold stan­dard in drug de­vel­op­ment. In our most re­cent sur­vey yes­ter­day, a plu­ral­i­ty of biotech ex­ecs vot­ed against sig­nif­i­cant changes at the agency, say­ing that re­forms over the past few years has al­ready sped up the process. And many of the ex­ecs that would like to see con­tin­ued change were clear­ly more in­ter­est­ed in specif­i­cal­ly tai­lored up­grades, not a whole­sale over­haul.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters